Skip to main content Skip to footer
HomeHome
 
  • Homepage
  • Searching for patents

    Patent knowledge

    Access our patent databases and search tools.

    Go to overview 

    • Overview
    • Technical information
      • Overview
      • Espacenet - patent search
      • European Publication Server
      • EP full-text search
    • Legal information
      • Overview
      • European Patent Register
      • European Patent Bulletin
      • European Case Law Identifier sitemap
      • Third-party observations
    • Business information
      • Overview
      • PATSTAT
      • IPscore
      • Technology insight reports
    • Data
      • Overview
      • Technology Intelligence Platform
      • Linked open EP data
      • Bulk data sets
      • Web services
      • Coverage, codes and statistics
    • Technology platforms
      • Overview
      • Plastics in transition
      • Water innovation
      • Space innovation
      • Technologies combatting cancer
      • Firefighting technologies
      • Clean energy technologies
      • Fighting coronavirus
    • Helpful resources
      • Overview
      • First time here?
      • Asian patent information
      • Patent information centres
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge
    Image
    Plastics in Transition

    Technology insight report on plastic waste management

  • Applying for a patent

    Applying for a patent

    Practical information on filing and grant procedures.

    Go to overview 

    • Overview
    • European route
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
      • Appeals
      • Unitary Patent & Unified Patent Court
      • National validation
      • Request for extension/validation
    • International route (PCT)
      • Overview
      • Euro-PCT Guide – PCT procedure at the EPO
      • EPO decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
      • Training and events
    • National route
    • Find a professional representative
    • MyEPO services
      • Overview
      • Understand our services
      • Get access
      • File with us
      • Interact with us on your files
      • Online Filing & fee payment outages
    • Forms
      • Overview
      • Request for examination
    • Fees
      • Overview
      • European fees (EPC)
      • International fees (PCT)
      • Unitary Patent fees (UP)
      • Fee payment and refunds
      • Warning

    UP

    Find out how the Unitary Patent can enhance your IP strategy

  • Law & practice

    Law & practice

    European patent law, the Official Journal and other legal texts.

    Go to overview 

    • Overview
    • Legal texts
      • Overview
      • European Patent Convention
      • Official Journal
      • Guidelines
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
      • Unitary patent system
      • National measures relating to the Unitary Patent
    • Court practices
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for professional representatives
    Image
    Law and practice scales 720x237

    Keep up with key aspects of selected BoA decisions with our monthly "Abstracts of decisions”

  • News & events

    News & events

    Our latest news, podcasts and events, including the European Inventor Award.

    Go to overview 

     

    • Overview
    • News
    • Events
    • European Inventor Award
      • Overview
      • About the award
      • Categories and prizes
      • Meet the finalists
      • Nominations
      • European Inventor Network
      • The 2024 event
    • Young Inventors Prize
      • Overview
      • About the prize
      • Nominations
      • The jury
      • The world, reimagined
      • The 2025 event
    • Press centre
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • Innovation and patenting in focus
      • Overview
      • Water-related technologies
      • CodeFest
      • Green tech in focus
      • Research institutes
      • Women inventors
      • Lifestyle
      • Space and satellites
      • The future of medicine
      • Materials science
      • Mobile communications
      • Biotechnology
      • Patent classification
      • Digital technologies
      • The future of manufacturing
      • Books by EPO experts
    • "Talk innovation" podcast

    Podcast

    From ideas to inventions: tune into our podcast for the latest in tech and IP

  • Learning

    Learning

    The European Patent Academy – the point of access to your learning

    Go to overview 

    • Overview
    • Learning activities and paths
      • Overview
      • Learning activities
      • Learning paths
    • EQE and EPAC
      • Overview
      • EQE - European qualifying examination
      • EPAC - European patent administration certification
      • CSP – Candidate Support Programme
    • Learning resources by area of interest
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
    • Learning resources by profile
      • Overview
      • Business and IP managers
      • EQE and EPAC Candidates
      • Judges, lawyers and prosecutors
      • National offices and IP authorities
      • Patent attorneys and paralegals
      • Universities, research centres and technology transfer centres (TTOs)
    Image
    Patent Academy catalogue

    Have a look at the extensive range of learning opportunities in the European Patent Academy training catalogue

  • About us

    About us

    Find out more about our work, values, history and vision

    Go to overview 

    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Overview
      • Official celebrations
      • Member states’ video statements
      • 50 Leading Tech Voices
      • Athens Marathon
      • Kids’ collaborative art competition
    • Legal foundations and member states
      • Overview
      • Legal foundations
      • Member states of the European Patent Organisation
      • Extension states
      • Validation states
    • Administrative Council and subsidiary bodies
      • Overview
      • Communiqués
      • Calendar
      • Documents and publications
      • Administrative Council
    • Principles & strategy
      • Overview
      • Our mission, vision, values and corporate policy
      • Strategic Plan 2028
      • Towards a New Normal
    • Leadership & management
      • Overview
      • President António Campinos
      • Management Advisory Committee
    • Sustainability at the EPO
      • Overview
      • Environmental
      • Social
      • Governance and Financial sustainability
    • Services & activities
      • Overview
      • Our services & structure
      • Quality
      • Consulting our users
      • European and international co-operation
      • European Patent Academy
      • Chief Economist
      • Ombuds Office
      • Reporting wrongdoing
    • Observatory on Patents and Technology
      • Overview
      • Technologies
      • Innovation actors
      • Policy and funding
      • Tools
      • About the Observatory
    • Procurement
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • Sustainable Procurement Policy
      • About eTendering and electronic signatures
      • Procurement portal
      • Invoicing
      • General conditions
      • Archived tenders
    • Transparency portal
      • Overview
      • General
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
    • Statistics and trends
      • Overview
      • Statistics & Trends Centre
      • Patent Index 2024
      • EPO Data Hub
      • Clarification on data sources
    • History
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s
    • Art collection
      • Overview
      • The collection
      • Let's talk about art
      • Artists
      • Media library
      • What's on
      • Publications
      • Contact
      • Culture Space A&T 5-10
      • "Long Night"
    Image
    Patent Index 2024 keyvisual showing brightly lit up data chip, tinted in purple, bright blue

    Track the latest tech trends with our Patent Index

 
en de fr
  • Language selection
  • English
  • Deutsch
  • Français
Main navigation
  • Homepage
    • Go back
    • New to patents
  • New to patents
    • Go back
    • Your business and patents
    • Why do we have patents?
    • What's your big idea?
    • Are you ready?
    • What to expect
    • How to apply for a patent
    • Is it patentable?
    • Are you first?
    • Patent quiz
    • Unitary patent video
  • Searching for patents
    • Go back
    • Overview
    • Technical information
      • Go back
      • Overview
      • Espacenet - patent search
        • Go back
        • Overview
        • National patent office databases
        • Global Patent Index (GPI)
        • Release notes
      • European Publication Server
        • Go back
        • Overview
        • Release notes
        • Cross-reference index for Euro-PCT applications
        • EP authority file
        • Help
      • EP full-text search
    • Legal information
      • Go back
      • Overview
      • European Patent Register
        • Go back
        • Overview
        • Release notes archive
        • Register documentation
          • Go back
          • Overview
          • Deep link data coverage
          • Federated Register
          • Register events
      • European Patent Bulletin
        • Go back
        • Overview
        • Download Bulletin
        • EP Bulletin search
        • Help
      • European Case Law Identifier sitemap
      • Third-party observations
    • Business information
      • Go back
      • Overview
      • PATSTAT
      • IPscore
        • Go back
        • Release notes
      • Technology insight reports
    • Data
      • Go back
      • Overview
      • Technology Intelligence Platform
      • Linked open EP data
      • Bulk data sets
        • Go back
        • Overview
        • Manuals
        • Sequence listings
        • National full-text data
        • European Patent Register data
        • EPO worldwide bibliographic data (DOCDB)
        • EP full-text data
        • EPO worldwide legal event data (INPADOC)
        • EP bibliographic data (EBD)
        • Boards of Appeal decisions
      • Web services
        • Go back
        • Overview
        • Open Patent Services (OPS)
        • European Publication Server web service
      • Coverage, codes and statistics
        • Go back
        • Weekly updates
        • Updated regularly
    • Technology platforms
      • Go back
      • Overview
      • Plastics in transition
        • Go back
        • Overview
        • Plastics waste recovery
        • Plastics waste recycling
        • Alternative plastics
      • Innovation in water technologies
        • Go back
        • Overview
        • Clean water
        • Protection from water
      • Space innovation
        • Go back
        • Overview
        • Cosmonautics
        • Space observation
      • Technologies combatting cancer
        • Go back
        • Overview
        • Prevention and early detection
        • Diagnostics
        • Therapies
        • Wellbeing and aftercare
      • Firefighting technologies
        • Go back
        • Overview
        • Detection and prevention of fires
        • Fire extinguishing
        • Protective equipment
        • Post-fire restoration
      • Clean energy technologies
        • Go back
        • Overview
        • Renewable energy
        • Carbon-intensive industries
        • Energy storage and other enabling technologies
      • Fighting coronavirus
        • Go back
        • Overview
        • Vaccines and therapeutics
          • Go back
          • Overview
          • Vaccines
          • Overview of candidate therapies for COVID-19
          • Candidate antiviral and symptomatic therapeutics
          • Nucleic acids and antibodies to fight coronavirus
        • Diagnostics and analytics
          • Go back
          • Overview
          • Protein and nucleic acid assays
          • Analytical protocols
        • Informatics
          • Go back
          • Overview
          • Bioinformatics
          • Healthcare informatics
        • Technologies for the new normal
          • Go back
          • Overview
          • Devices, materials and equipment
          • Procedures, actions and activities
          • Digital technologies
        • Inventors against coronavirus
    • Helpful resources
      • Go back
      • Overview
      • First time here?
        • Go back
        • Overview
        • Basic definitions
        • Patent classification
          • Go back
          • Overview
          • Cooperative Patent Classification (CPC)
        • Patent families
          • Go back
          • Overview
          • DOCDB simple patent family
          • INPADOC extended patent family
        • Legal event data
          • Go back
          • Overview
          • INPADOC classification scheme
      • Asian patent information
        • Go back
        • Overview
        • China (CN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Chinese Taipei (TW)
          • Go back
          • Overview
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • India (IN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
        • Japan (JP)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Korea (KR)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Russian Federation (RU)
          • Go back
          • Overview
          • Facts and figures
          • Numbering system
          • Searching in databases
        • Useful links
      • Patent information centres (PATLIB)
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge
  • Applying for a patent
    • Go back
    • Overview
    • European route
      • Go back
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
        • Go back
        • Oral proceedings calendar
          • Go back
          • Calendar
          • Public access to appeal proceedings
          • Public access to opposition proceedings
          • Technical guidelines
      • Appeals
      • Unitary Patent & Unified Patent Court
        • Go back
        • Overview
        • Unitary Patent
          • Go back
          • Overview
          • Legal framework
          • Main features
          • Applying for a Unitary Patent
          • Cost of a Unitary Patent
          • Translation and compensation
          • Start date
          • Introductory brochures
        • Unified Patent Court
      • National validation
      • Extension/validation request
    • International route
      • Go back
      • Overview
      • Euro-PCT Guide
      • Entry into the European phase
      • Decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
        • Go back
        • Patent Prosecution Highway (PPH) programme outline
      • Training and events
    • National route
    • MyEPO services
      • Go back
      • Overview
      • Understand our services
        • Go back
        • Overview
        • Exchange data with us using an API
          • Go back
          • Release notes
      • Get access
        • Go back
        • Overview
        • Release notes
      • File with us
        • Go back
        • Overview
        • What if our online filing services are down?
        • Release notes
      • Interact with us on your files
        • Go back
        • Release notes
      • Online Filing & fee payment outages
    • Fees
      • Go back
      • Overview
      • European fees (EPC)
        • Go back
        • Overview
        • Decisions and notices
      • International fees (PCT)
        • Go back
        • Reduction in fees
        • Fees for international applications
        • Decisions and notices
        • Overview
      • Unitary Patent fees (UP)
        • Go back
        • Overview
        • Decisions and notices
      • Fee payment and refunds
        • Go back
        • Overview
        • Payment methods
        • Getting started
        • FAQs and other documentation
        • Technical information for batch payments
        • Decisions and notices
        • Release notes
      • Warning
    • Forms
      • Go back
      • Overview
      • Request for examination
    • Find a professional representative
  • Law & practice
    • Go back
    • Overview
    • Legal texts
      • Go back
      • Overview
      • European Patent Convention
        • Go back
        • Overview
        • Archive
          • Go back
          • Overview
          • Documentation on the EPC revision 2000
            • Go back
            • Overview
            • Diplomatic Conference for the revision of the EPC
            • Travaux préparatoires
            • New text
            • Transitional provisions
            • Implementing regulations to the EPC 2000
            • Rules relating to Fees
            • Ratifications and accessions
          • Travaux Préparatoires EPC 1973
      • Official Journal
      • Guidelines
        • Go back
        • Overview
        • EPC Guidelines
        • PCT-EPO Guidelines
        • Unitary Patent Guidelines
        • Guidelines revision cycle
        • Consultation results
        • Summary of user responses
        • Archive
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
        • Go back
        • Overview
        • Archive
      • Unitary Patent system
        • Go back
        • Travaux préparatoires to UP and UPC
      • National measures relating to the Unitary Patent 
    • Court practices
      • Go back
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Go back
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Go back
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for professional representatives
  • News & events
    • Go back
    • Overview
    • News
    • Events
    • European Inventor Award
      • Go back
      • Overview
      • About the award
      • Categories and prizes
      • Meet the inventors
      • Nominations
      • European Inventor Network
        • Go back
        • 2024 activities
        • 2025 activities
        • Rules and criteria
        • FAQ
      • The 2024 event
    • Young Inventors Prize
      • Go back
      • Overview
      • About the prize
      • Nominations
      • The jury
      • The world, reimagined
      • The 2025 event
    • Press centre
      • Go back
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
        • Go back
        • Overview
        • European Patent Office
        • Q&A on patents related to coronavirus
        • Q&A on plant patents
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • In focus
      • Go back
      • Overview
      • Water-related technologies
      • CodeFest
        • Go back
        • CodeFest Spring 2025 on classifying patent data for sustainable development
        • Overview
        • CodeFest 2024 on generative AI
        • CodeFest 2023 on Green Plastics
      • Green tech in focus
        • Go back
        • Overview
        • About green tech
        • Renewable energies
        • Energy transition technologies
        • Building a greener future
      • Research institutes
      • Women inventors
      • Lifestyle
      • Space and satellites
        • Go back
        • Overview
        • Patents and space technologies
      • Healthcare
        • Go back
        • Overview
        • Medical technologies and cancer
        • Personalised medicine
      • Materials science
        • Go back
        • Overview
        • Nanotechnology
      • Mobile communications
      • Biotechnology
        • Go back
        • Overview
        • Red, white or green
        • The role of the EPO
        • What is patentable?
        • Biotech inventors
      • Classification
        • Go back
        • Overview
        • Nanotechnology
        • Climate change mitigation technologies
          • Go back
          • Overview
          • External partners
          • Updates on Y02 and Y04S
      • Digital technologies
        • Go back
        • Overview
        • About ICT
        • Hardware and software
        • Artificial intelligence
        • Fourth Industrial Revolution
      • Additive manufacturing
        • Go back
        • Overview
        • About AM
        • AM innovation
      • Books by EPO experts
    • Podcast
  • Learning
    • Go back
    • Overview
    • Learning activities and paths
      • Go back
      • Overview
      • Learning activities: types and formats
      • Learning paths
    • EQE and EPAC
      • Go back
      • Overview
      • EQE - European Qualifying Examination
        • Go back
        • Overview
        • Compendium
          • Go back
          • Overview
          • Paper F
          • Paper A
          • Paper B
          • Paper C
          • Paper D
          • Pre-examination
        • Candidates successful in the European qualifying examination
        • Archive
      • EPAC - European patent administration certification
      • CSP – Candidate Support Programme
    • Learning resources by area of interest
      • Go back
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
    • Learning resources by profile
      • Go back
      • Overview
      • Business and IP managers
        • Go back
        • Overview
        • Innovation case studies
          • Go back
          • Overview
          • SME case studies
          • Technology transfer case studies
          • High-growth technology case studies
        • Inventor's handbook
          • Go back
          • Overview
          • Introduction
          • Disclosure and confidentiality
          • Novelty and prior art
          • Competition and market potential
          • Assessing the risk ahead
          • Proving the invention
          • Protecting your idea
          • Building a team and seeking funding
          • Business planning
          • Finding and approaching companies
          • Dealing with companies
        • Best of search matters
          • Go back
          • Overview
          • Tools and databases
          • EPO procedures and initiatives
          • Search strategies
          • Challenges and specific topics
        • Support for high-growth technology businesses
          • Go back
          • Overview
          • Business decision-makers
          • IP professionals
          • Stakeholders of the Innovation Ecosystem
      • EQE and EPAC Candidates
        • Go back
        • Overview
        • Paper F brain-teasers
        • Daily D questions
        • European qualifying examination - Guide for preparation
        • EPAC
      • Judges, lawyers and prosecutors
        • Go back
        • Overview
        • Compulsory licensing in Europe
        • The jurisdiction of European courts in patent disputes
      • National offices and IP authorities
        • Go back
        • Overview
        • Learning material for examiners of national officers
        • Learning material for formalities officers and paralegals
      • Patent attorneys and paralegals
      • Universities, research centres and TTOs
        • Go back
        • Overview
        • Modular IP Education Framework (MIPEF)
        • Pan-European Seal Young Professionals Programme
          • Go back
          • Overview
          • For students
          • For universities
            • Go back
            • Overview
            • IP education resources
            • University memberships
          • Our young professionals
          • Professional development plan
        • Academic Research Programme
          • Go back
          • Overview
          • Completed research projects
          • Current research projects
        • IP Teaching Kit
          • Go back
          • Overview
          • Download modules
        • Intellectual property course design manual
        • PATLIB Knowledge Transfer to Africa
          • Go back
          • Core activities
          • Stories and insights
  • About us
    • Go back
    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Go back
      • Official celebrations
      • Overview
      • Member states’ video statements
        • Go back
        • Albania
        • Austria
        • Belgium
        • Bulgaria
        • Croatia
        • Cyprus
        • Czech Republic
        • Denmark
        • Estonia
        • Finland
        • France
        • Germany
        • Greece
        • Hungary
        • Iceland
        • Ireland
        • Italy
        • Latvia
        • Liechtenstein
        • Lithuania
        • Luxembourg
        • Malta
        • Monaco
        • Montenegro
        • Netherlands
        • North Macedonia
        • Norway
        • Poland
        • Portugal
        • Romania
        • San Marino
        • Serbia
        • Slovakia
        • Slovenia
        • Spain
        • Sweden
        • Switzerland
        • Türkiye
        • United Kingdom
      • 50 Leading Tech Voices
      • Athens Marathon
      • Kids’ collaborative art competition
    • Legal foundations and member states
      • Go back
      • Overview
      • Legal foundations
      • Member states
        • Go back
        • Overview
        • Member states by date of accession
      • Extension states
      • Validation states
    • Administrative Council and subsidiary bodies
      • Go back
      • Overview
      • Communiqués
        • Go back
        • 2024
        • Overview
        • 2023
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
        • 2017
        • 2016
        • 2015
        • 2014
        • 2013
      • Calendar
      • Documents and publications
        • Go back
        • Overview
        • Select Committee documents
      • Administrative Council
        • Go back
        • Overview
        • Composition
        • Representatives
        • Rules of Procedure
        • Board of Auditors
        • Secretariat
        • Council bodies
    • Principles & strategy
      • Go back
      • Overview
      • Mission, vision, values & corporate policy
      • Strategic Plan 2028
        • Go back
        • Driver 1: People
        • Driver 2: Technologies
        • Driver 3: High-quality, timely products and services
        • Driver 4: Partnerships
        • Driver 5: Financial sustainability
      • Towards a New Normal
      • Data protection & privacy notice
    • Leadership & management
      • Go back
      • Overview
      • About the President
      • Management Advisory Committee
    • Sustainability at the EPO
      • Go back
      • Overview
      • Environmental
        • Go back
        • Overview
        • Inspiring environmental inventions
      • Social
        • Go back
        • Overview
        • Inspiring social inventions
      • Governance and Financial sustainability
    • Procurement
      • Go back
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • Dynamic Purchasing System (DPS) publications
      • Sustainable Procurement Policy
      • About eTendering
      • Invoicing
      • Procurement portal
        • Go back
        • Overview
        • e-Signing contracts
      • General conditions
      • Archived tenders
    • Services & activities
      • Go back
      • Overview
      • Our services & structure
      • Quality
        • Go back
        • Overview
        • Foundations
          • Go back
          • Overview
          • European Patent Convention
          • Guidelines for examination
          • Our staff
        • Enabling quality
          • Go back
          • Overview
          • Prior art
          • Classification
          • Tools
          • Processes
        • Products & services
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
          • Continuous improvement
        • Quality through networking
          • Go back
          • Overview
          • User engagement
          • Co-operation
          • User satisfaction survey
          • Stakeholder Quality Assurance Panels
        • Patent Quality Charter
        • Quality Action Plan
        • Quality dashboard
        • Statistics
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
        • Integrated management at the EPO
      • Consulting our users
        • Go back
        • Overview
        • Standing Advisory Committee before the EPO (SACEPO)
          • Go back
          • Overview
          • Objectives
          • SACEPO and its working parties
          • Meetings
          • Single Access Portal – SACEPO Area
        • Surveys
          • Go back
          • Overview
          • Detailed methodology
          • Search services
          • Examination services, final actions and publication
          • Opposition services
          • Formalities services
          • Customer services
          • Filing services
          • Key Account Management (KAM)
          • Website
          • Archive
      • Our user service charter
      • European and international co-operation
        • Go back
        • Overview
        • Co-operation with member states
          • Go back
          • Overview
        • Bilateral co-operation with non-member states
          • Go back
          • Overview
          • Validation system
          • Reinforced Partnership programme
        • Multilateral international co-operation with IP offices and organisations
        • Co-operation with international organisations outside the IP system
      • European Patent Academy
        • Go back
        • Overview
        • Partners
      • Chief Economist
        • Go back
        • Overview
        • Economic studies
      • Ombuds Office
      • Reporting wrongdoing
    • Observatory on Patents and Technology
      • Go back
      • Overview
      • Technologies
        • Go back
        • Overview
        • Innovation against cancer
        • Assistive robotics
        • Space technologies
      • Innovation actors
        • Go back
        • Overview
        • Startups and SMEs
          • Go back
          • Overview
          • Publications
        • Research universities and public research organisations
      • Policy and funding
        • Go back
        • Overview
        • Financing innovation programme
          • Go back
          • Overview
          • Our studies on the financing of innovation
          • EPO initiatives for patent applicants
          • Financial support for innovators in Europe
        • Patents and standards
          • Go back
          • Overview
          • Publications
          • Patent standards explorer
      • Tools
        • Go back
        • Overview
        • Deep Tech Finder
      • About the Observatory
        • Go back
        • Overview
        • Work plan
    • Transparency portal
      • Go back
      • Overview
      • General
        • Go back
        • Overview
        • Annual Review 2023
          • Go back
          • Overview
          • Foreword
          • Executive summary
          • 50 years of the EPC
          • Strategic key performance indicators
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
        • Annual Review 2022
          • Go back
          • Overview
          • Foreword
          • Executive summary
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
    • Statistics and trends
      • Go back
      • Overview
      • Statistics & Trends Centre
      • Patent Index 2024
        • Go back
        • Insight into computer technology and AI
        • Insight into clean energy technologies
        • Statistics and indicators
          • Go back
          • European patent applications
            • Go back
            • Key trend
            • Origin
            • Top 10 technical fields
              • Go back
              • Computer technology
              • Electrical machinery, apparatus, energy
              • Digital communication
              • Medical technology
              • Transport
              • Measurement
              • Biotechnology
              • Pharmaceuticals
              • Other special machines
              • Organic fine chemistry
            • All technical fields
          • Applicants
            • Go back
            • Top 50
            • Categories
            • Women inventors
          • Granted patents
            • Go back
            • Key trend
            • Origin
            • Designations
      • Data to download
      • EPO Data Hub
      • Clarification on data sources
    • History
      • Go back
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s
    • Art collection
      • Go back
      • Overview
      • The collection
      • Let's talk about art
      • Artists
      • Media library
      • What's on
      • Publications
      • Contact
      • Culture Space A&T 5-10
        • Go back
        • Catalyst lab & Deep vision
          • Go back
          • Irene Sauter (DE)
          • AVPD (DK)
          • Jan Robert Leegte (NL)
          • Jānis Dzirnieks (LV) #1
          • Jānis Dzirnieks (LV) #2
          • Péter Szalay (HU)
          • Thomas Feuerstein (AT)
          • Tom Burr (US)
          • Wolfgang Tillmans (DE)
          • TerraPort
          • Unfinished Sculpture - Captives #1
          • Deep vision – immersive exhibition
          • Previous exhibitions
        • The European Patent Journey
        • Sustaining life. Art in the climate emergency
        • Next generation statements
        • Open storage
        • Cosmic bar
      • "Long Night"
  • Boards of Appeal
    • Go back
    • Overview
    • Decisions of the Boards of Appeal
      • Go back
      • Overview
      • Recent decisions
      • Selected decisions
    • Information from the Boards of Appeal
    • Procedure
    • Oral proceedings
    • About the Boards of Appeal
      • Go back
      • Overview
      • President of the Boards of Appeal
      • Enlarged Board of Appeal
        • Go back
        • Overview
        • Pending referrals (Art. 112 EPC)
        • Decisions sorted by number (Art. 112 EPC)
        • Pending petitions for review (Art. 112a EPC)
        • Decisions on petitions for review (Art. 112a EPC)
      • Technical Boards of Appeal
      • Legal Board of Appeal
      • Disciplinary Board of Appeal
      • Presidium
        • Go back
        • Overview
    • Code of Conduct
    • Business distribution scheme
      • Go back
      • Overview
      • Technical boards of appeal by IPC in 2025
      • Archive
    • Annual list of cases
    • Communications
    • Annual reports
      • Go back
      • Overview
    • Publications
      • Go back
      • Abstracts of decisions
    • Case Law of the Boards of Appeal
      • Go back
      • Overview
      • Archive
  • Service & support
    • Go back
    • Overview
    • Website updates
    • Availability of online services
      • Go back
      • Overview
    • FAQ
      • Go back
      • Overview
    • Publications
    • Ordering
      • Go back
      • Overview
      • Patent Knowledge Products and Services
      • Terms and conditions
        • Go back
        • Overview
        • Patent information products
        • Bulk data sets
        • Open Patent Services (OPS)
        • Fair use charter
    • Procedural communications
    • Useful links
      • Go back
      • Overview
      • Patent offices of member states
      • Other patent offices
      • Directories of patent attorneys
      • Patent databases, registers and gazettes
      • Disclaimer
    • Contact us
      • Go back
      • Overview
      • Filing options
      • Locations
    • Subscription centre
      • Go back
      • Overview
      • Subscribe
      • Change preferences
      • Unsubscribe
    • Official holidays
    • Glossary
    • RSS feeds
Board of Appeals
Decisions

Recent decisions

Overview
  • 2025 decisions
  • 2024 decisions
  • 2023 decisions
  1. Home
  2. T 2900/18 (Treatment of glomerulonephritis/R-PHARM) 23-06-2022
Facebook X Linkedin Email

T 2900/18 (Treatment of glomerulonephritis/R-PHARM) 23-06-2022

European Case Law Identifier
ECLI:EP:BA:2022:T290018.20220623
Date of decision
23 June 2022
Case number
T 2900/18
Petition for review of
-
Application number
12174216.7
IPC class
C07K 16/24
C07K 16/28
A61P 13/12
Language of proceedings
EN
Distribution
NO DISTRIBUTION (D)

Download and more information:

Decision in EN 370.19 KB
Documentation of the appeal procedure can be found in the European Patent Register
Bibliographic information is available in:
EN
Versions
Unpublished
Application title

Method for the treatment of glomerulonephritis

Applicant name
R-Pharm International, LLC
Opponent name
Ablynx N.V.
Board
3.3.04
Headnote
-
Relevant legal provisions
European Patent Convention Art 54
Keywords
Novelty - (no)
Catchword
-
Cited decisions
-
Citing decisions
-

I. European patent No. 2 527 371, entitled "Method for the treatment of glomerulonephritis" was opposed under Article 100(a) in combination with Articles 54 and 56 EPC and Article 100(b) and (c) EPC.

II. The patent was granted with claim 1 as follows:

"1. An inhibitor of IL-6 activity which is an antibody or functionally-active fragment, which antibody or functionally-active fragment selectively interacts with an IL-6 polypeptide or an IL-6R polypeptide for use in the treatment and/or prophylaxis of glomerulonephritis associated with a vasculitic disorder".

III. In the decision under appeal, the opposition division considered grounds of opposition raised under Article l00(a) EPC in combination with Articles 54 and 56 EPC and Article l00(b) and (c) EPC.

IV. The opposition division decided to reject the opposition. An appeal was filed by the opponent (appellant) against this decision. The patent proprietor is respondent to this appeal.

V. With the statement of grounds of appeal, the appellant submitted documents D26 to D28.

VI. The respondent replied to the statement of grounds of appeal, requesting as its main and sole request that the appeal be dismissed and that the patent be maintained as granted.

VII. Following documents are mentioned in this decision.

D1: Liang B., Gardner D.B., Griswold D.E., Bugelski P.J., Song X.Y.R., 2006, "Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus", Immunology, 119, 296-305.

D7: Kitching A.R., Holdsworth S.R., Hickey M.J., 2008, "Targeting Leukocytes in Immune Glomerular Diseases". Curr. Med. Chem., 15, 448-458.

D8: Guillevin, L., Dörner, T., 2007, "Vasculitis: mechanisms involved and clinical manifestations". Arthritis Res Ther, 9(Suppl 2), S9.

D14: EP 1 004 315 A1

VIII. Oral proceedings before the board were held as scheduled. At the end of these proceedings, the Chair announced the decision of the board.

IX. The submissions of the appellant are summarised as follows.

Main request(maintenance of the patent as granted) - claim 1

Claim construction

The claim was for a second medical use. The medical purpose mentioned in the claim was the treatment and/or prophylaxis of glomerulonephritis associated with a vasculitic disorder. The skilled person would understand that "associated with" glomerulonephritis did not mean that the glomerulonephritis was necessarily caused by the vasculitic disorder (or vice-versa). Instead, it was sufficient that e.g., the glomerulonephritis and the vasculitic disorder appeared at the same time in the same organism. In any case, "glomerulonephritis associated with a vasculitic disorder" included glomerulonephritis associated with a disease or disorder that itself was associated a vasculitic disorder.

The novelty of the claimed subject-matter hinged on the interpretation of the expression "glomerulonephritis associated with a vasculitic disorder" found in the independent claims. In the decision under appeal, the opposition division took the view that 'associated with' simply meant 'connected with', which, led it to conclude that the claimed treatment with the anti-IL-6 antibody must involve both diseases.

However, the correct interpretation of "associated with" did not necessarily imply that the glomerulonephritis had to be caused or somehow characterised by the vasculitic disorder (or that the vasculitic disorder is caused or characterised by the glomerulonephritis, for that matter). Instead, a loose "association" between the glomerulonephritis and a vasculitic disorder was encompassed by the expression used in the claims.

Novelty (Article 54 EPC)

Document D1

Document D1 disclosed an anti-IL-6 antibody for use in treating glomerulonephritis in murine systemic lupus erythematosus (SLE) cases (see page 300; Figures 4e and 4f and Table 1). The authors of document D1 observed periarterial inflammatory infiltrate that was reduced by treatment with an anti-IL-6 antibody. Accordingly, the mice used in document D1 had glomerulonephritis associated with vasculitis. Thus, the anti-IL-6 antibody reduced glomerulonephritis associated with (arterial) vasculitis. The claimed subject-matter therefore lacked novelty.

Document D14

Document D14 disclosed an anti-IL-6 receptor (IL-6R) antibody for use as a preventive and/or therapeutic agent for nephritis in murine SLE. This antibody inhibited the binding of IL-6 to IL-6R thereby neutralising the biological activity of IL-6.

The experiments disclosed in document D14 demonstrated that administration of anti-IL-6R antibody markedly delayed the appearance of urinary protein and markedly suppressed the incidence of the disease (see paragraph [0152]). The IL-6R antibody also prolonged the survival of NZB/W F1 mice (see paragraph [0153]).

Document D14 disclosed the treatment of "glomerulonephritis associated with a vasculitic disorder" because glomerulonephritis was a pathological hallmark feature of SLE (see document D1, pages 297 and 300, left column, or document D7, Table 3) and SLE was associated with vasculitis (see, e.g. document D8, page 2, left column). Accordingly, the mice treated in document D14 had a "glomerulonephritis associated with a vasculitic disorder" as illustrated below (illustration taken from page 13 of the statement of grounds of appeal).

FORMULA/TABLE/GRAPHIC

X. The submissions of the respondent are summarised as follows.

Main request (maintenance of the patent as granted) - claim 1

Claim construction

The skilled person would have considered that the therapeutic aim of the claimed product was treatment of "glomerulonephritis associated with a vasculitic disorder". This referred only to glomerulonephritis caused by the disease it was associated with (emphasis added by the board). The patent clearly defined that diseases such Goodpasture's syndrome, vasculitis and IgA nephropathy presented glomerulonephritis as a consequence of the disease and not as a possible concomitant occurrence of two separate diseases.

The expression "glomerulonephritis associated with a vasculitic disorder" did not include cases where the glomerulonephritis and the vasculitic disorder were symptoms of the same disease/disorder if they did not occur in the same patient and/or at the same time in a patient.

Novelty (Article 54 EPC)

Document D1

The teaching of document D1 was largely similar to that in document D14 (see below). It openly acknowledged that NZB/W F1 mice were an accepted model of lupus nephritis (page 297 left hand column, last paragraph).

The skilled person would not even have considered that document D1 disclosed an anti-IL6 antibody for treating for lupus nephritis, let alone glomerulonephritis associated with a vasculitic disorder. Table 1, in document D1 in fact disclosed that there was no statistically significant difference in the median between control antibody and anti-IL-6 monoclonal antibody. This was further repeated at page 300, right hand column, mid paragraph: "Histopathological analysis showed that treatment with anti-IL6 mAb significantly reduced the disease severity to that of WHO class II to III disease". Thus, according to the table at page 296 of D1, the disease severity was still high but not as severe as a classification in group IV-VI.

Document D14

Document D14 was silent about treating glomerulonephritis associated with a vasculitic disorder nor was this information directly and unambiguously derivable from the prior art. The skilled person would have known that document D14 included data coming from the NZB/W mouse model of nephritis associated with SLE, which was not suitable for studying other diseases such as "glomerulonephritis associated with a vasculitic disorder". Accordingly, the skilled person would not have considered that document D14 clearly and unambiguously provided evidence that glomerulonephritis associated with a vasculitic disorder could be treated.

XI. The appellant requested that the decision under appeal be set aside and that the European patent No. 25 27 371 be revoked. Furthermore, documents D26 to D28, filed with the statement setting out the grounds of appeal, should be admitted into the appeal proceedings.

XII. The respondent requested that the appeal be dismissed. Moreover, documents D26 to D28, as well as documents D6, D9, D10 and D13, should be held inadmissible.

Admittance of documents

1. The board reached its decision without needing to take documents D26 to D28 or D6, D9, D10 and D13 into account. It is therefore not necessary to decide on their admittance.

Main request - Claim 1

Claim construction

2. The claim is for a purpose-limited product under Article 54(5) EPC, i.e. a so-called second or further medical use. The product is "an inhibitor of IL-6 activity which is an antibody or functionally-active fragment". The board will in this decision use "antibody" to refer to both the antibody and its functionally active fragment. The claimed antibody is further defined by its function, that function being the ability to selectively interact with an IL-6 polypeptide or an IL-6R polypeptide. The therapeutic purpose is "the treatment and/or prophylaxis of glomerulonephritis associated with a vasculitic disorder". The board will refer to the claim as having feature (a): "an inhibitor of IL-6 activity which is an antibody or functionally-active fragment, which antibody or functionally-active fragment selectively interacts with an IL-6 polypeptide or an IL-6R polypeptide" and feature (b): "for use in the treatment and/or prophylaxis of glomerulonephritis associated with a vasculitic disorder", where "glomerulonephritis associated with a vasculitic disorder" is a sub-category of glomerulonephritis in general.

3. There was disagreement between the parties about how the skilled person would interpret feature (b). The respondent was of the view that the skilled person would consider that it referred only to glomerulonephritis caused by a disease it was associated with. The appellant on the other hand argued that "glomerulonephritis associated with a vasculitic disorder" included glomerulonephritis associated with a disease or disorder that itself was associated a vasculitic disorder (see Sections IX. and X.).

4. The board construes the claim in accordance with the principles developed in the case law of the boards of appeal. Thus, terms in claims are given their normal meaning in the relevant art (see Case Law of the Boards of Appeal of the European Patent Office, 9th edition 2019, II.A. 6.3.3). In the present case, it is necessary to construe the expression "glomerulonephritis associated with a vasculitic disorder". It is noted that no case has been made by either party that the expression had a special meaning to the skilled person. Moreover, the description of the patent contains no definition of what "associated" is intended to mean or of what is to be understood by "vasculitic disorder". Instead, paragraph [0008] defines vasculitis as including "systemic and small vessel vasculitis such as that associated with diseases with anti-neutrophil circulating antibodies, for example, Wegener's disease (also called Wegener's granulomatosus). Wegener's disease involves inflammation of the arteries of the lungs, nasal passages and kidneys".

5. The board understands that "vasculitis" being a subclass of "vasculitic disorder". From the use of "such as" in paragraph [0008] it is understood that Wegener's disease is given merely as an example of a disease associated with vasculitis. In other words, Wegener's disease cannot be the only disease in which glomerulonephritis is associated with a vasculitic disorder. This conclusion is supported throughout the description where "a vasculitic disorder" and "Wegener's disease" are listed separately, see e.g. paragraph [0001] of the patent, implying that they are not equivalent.

6. In the absence of any definition of "associated", the board considers that the skilled person would interpret the term to mean in some way "linked to". Thus, "glomerulonephritis associated with a vasculitic disorder" would be understood to be a glomerulonephritis linked to a vasculitic disorder. A link could exist, for instance if the glomerulonephritis were part of the same disease complex as a vasculitic disorder.

Novelty (Article 54 EPC)

Document D1

7. Document D1 discloses an anti-IL-6 antibody for use in treating SLE. It is entitled "Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus" (see title). It describes a study on "NZB/W F1 mice that spontaneously develop an autoantibody response against DNA and chromatin antigens as well as polyclonal hypergammaglobulinaemia and ultimately severe immune complex-mediated glomerulonephritis". These mice "have been widely used as a model to study lupus nephritis" (see page 297, left column). It concludes that "Upon administration of anti-IL-6 mAb in our studies, the disease severity of glomerulonephritis was significantly reduced in NZB/W F1 mice" (see page 304, left column)".

8. In view of its effect on NZB/W F1 mice, it is concluded that document D1 discloses feature (a) of claim 1, i.e. an anti-IL-6 antibody which acts as an inhibitor of IL-6 activity. Regarding feature (b), document D1 discloses use of an anti-IL-6 antibody for inhibiting autoimmune responses, which inter alia lead to glomerulonephritis. Thus, document D1 discloses an anti-IL-6 antibody for use in treating glomerulonephritis associated with systemic lupus erythematosus (SLE).

9. The respondent's argument that document D1 does not disclose the use of an anti-IL-6 antibody for the treatment of lupus nephritis is not persuasive. As pointed out by the respondent itself, page 300, right-hand column, discloses that "Histopathological analysis showed that treatment with anti-IL6 mAb significantly reduced the disease severity to that of WHO class II to III disease". Contrary to the respondent's view, a treatment of a disease is disclosed in a document even if the treatment only reduces the severity of the disease.

10. Furthermore, it was not disputed by the respondent that, as disclosed in document D8 (see page 2, left-hand column, paragraph 1), vasculitis may occur as a symptom of SLE. Document D8 is an article entitled "Vasculitis: mechanisms involved and clinical manifestations". It discloses that "...there is evidence to suggest that vasculitis accelerating atherosclerosis is a complicating feature of most, possibly all, autoimmune diseases. This includes connective tissue diseases (CTDs) such as rheumatoid arthritis (RA), scleroderma, sarcoidosis and systemic lupus erythematosus (SLE)" (see page 1, paragraph 1; emphasis added by the board). Furthermore, on page 2 (left column, Figure 1 and paragraph 1) it is explained that "The vasculitides that occur in autoimmune diseases usually affect small-sized vessels, as is the case in SLE, systemic sclerosis and Sjogren's syndrome".

11. The respondent's argument in favour of novelty of the claimed subject-matter over that disclosed in document D1 relies on the construction of the phrase "glomerulonephritis associated with a vasculitic disorder" as not including glomerulonephritis occurring in SLE.

12. However, as set out in the section on claim construction above (see points 2. to 6.), the board has decided that the glomerulonephritis to be treated by the claimed product includes any that is associated or linked to vasculitis. Since it has been convincingly established that both glomerulonephritis and vasculitis occur in SLE, the board considers that document D1 discloses anti-IL-6 antibodies for use in treating "glomerulonephritis associated with a vasculitic disorder", i.e. a disease as claimed.

13. In view of the claim construction, the fact that document D1 does not disclose treating an SLE patient simultaneously having both glomerulonephritis and vasculitis, is not relevant as this is not a feature of the claim.

Document D14

14. The board also considers that the disclosure in document D14 anticipates the claimed subject-matter. The considerations are similar to those given above in relation to document D1, since they also turn on whether or not treating glomerulonephritis associated with SLE falls within the meaning of "glomerulonephritis associated with a vasculitic disorder".

15. Document D14 discloses anti-IL-6 receptor (IL-6R) antibodies for treating SLE, for instance paragraph [0018] reads "The present invention provides a preventive and/or therapeutic agent for systemic lupus erythematosus comprising an anti-IL-6 receptor antibody as an active ingredient". Indeed document D14 uses the same mouse model of SLE as used in document D1, NZB/W F1 mice. It discloses that IL-6R antibodies inhibit the binding of IL-6 to IL-6R, neutralizing the activity of IL-6 (see paragraph [0032]). The experiments reported in document D14 demonstrate that the timing of appearance of urinary protein was markedly delayed, and the incidence of the disease was also markedly suppressed ([0152]). The IL-6R antibody prolonged the days of survival ([0153]). It was not in dispute that the presence of urinary protein was a symptom of glomerulonephritis.

16. Given the claim construction applied by the board (see point 6., above), SLE is a disease in which patients suffer from both glomerulonephritis and vasculitic disorders (vasculitis). Thus, the treatment of glomerulonephritis associated with SLE is also treatment of glomerulonephritis associated with a vasculitic disorder. Therefore, the disclosure in document D14 anticipates the subject-matter of claim 1.

17. Since the subject matter of claim 1 of the patent as granted lacks novelty and no other claim requests are on file, the patent must be revoked.

Order

For these reasons it is decided that:

1. The decision under appeal is set aside.

2. The patent is revoked.

Footer - Service & support
  • Service & support
    • Website updates
    • Availability of online services
    • FAQ
    • Publications
    • Procedural communications
    • Contact us
    • Subscription centre
    • Official holidays
    • Glossary
Footer - More links
  • Jobs & careers
  • Press centre
  • Single Access Portal
  • Procurement
  • Boards of Appeal
Facebook
European Patent Office
EPO Jobs
Instagram
EuropeanPatentOffice
Linkedin
European Patent Office
EPO Jobs
EPO Procurement
X (formerly Twitter)
EPOorg
EPOjobs
Youtube
TheEPO
Footer
  • Legal notice
  • Terms of use
  • Data protection and privacy
  • Accessibility